MedChemExpress MCE - Products
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use.
| Product | Description | |
|---|---|---|
| JA310 | JA310, a chemical probe, is a highly selective MST3 kinase inhibitor. JA310 has high cellular potency against MST3 with an EC50 value of 106 nM[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 3022928-90-8. Pack Sizes: 5 mg; 10 mg; 25 mg. Product ID: HY-160211. |  |
| JAB-2485 | JAB-2485 is an orally active and selective Aurora kinase A (AURKA) inhibitor with an IC50 value of 0.327 nM. JAB-2485 exhibits inhibitory activity against various tumor cell lines such as neuroblastoma, triple-negative breast cancer, small cell lung cancer, and epithelial ovarian cancer. JAB-2485 can induce cell cycle arrest and apoptosis in tumor cells. JAB-2485 has antitumor activity[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2899209-55-1. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg. Product ID: HY-157396. | |
| JAB-3068 | JAB-3068 (SHP2-IN-6) is a potent SHP2 inhibitor, extracted from patent WO2017211303A1, compound 7, has an IC50 of 25.8 nM[1]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: SHP2-IN-6. CAS No. 2169223-48-5. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-131132. | |
| Jaceosidin | Jaceosidin is a flavonoid isolated from Artemisia vestita, induces apoptosis in cancer cells, activates Bax and down-regulates Mcl-1 and c-FLIP expression[1]. Jaceosidin exhibits anti-cancer[2], anti-inflammatory activities, decreases leves of inflammatory markers, and suppresses COX-2 expression and NF-κB activation[3]. Uses: Scientific research. Category: Signaling pathways. CAS No. 18085-97-7. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg. Product ID: HY-N0831. | |
| Jagged-1 (188-204) | Jagged-1 (188-204) is a fragment of the Jagged-1 (JAG-1) protein with Notch agonist activity. JAG-1 is a Notch ligand highly expressed in cultured and primary multiple myeloma (MM) cells. JAG-1 induces maturation of monocyte-derived human dendritic cells[1][2][3]. Uses: Scientific research. Category: Signaling pathways. CAS No. 219127-21-6. Pack Sizes: 5 mg; 10 mg; 25 mg. Product ID: HY-P1846. | |
| JAK1/2 ligand 1 | JAK1/2 ligand 1 is the ligand of JAK1/2 and can be used for the synthesis of PROTACs, such as JAK1/2 Ligand-Linker Conjugates 1 (HY-179716)[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1026028-96-5. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 250 mg. Product ID: HY-179716. | |
| JAK1-IN-13 | JAK1-IN-13 (compound 36b) is an orally active, potent and highly selective inhibitor of JAK1 with an IC50 of 0.044 nM. JAK1-IN-13 significantly decreases STAT3 phosphorylation[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2778330-90-6. Pack Sizes: 5 mg; 10 mg; 25 mg. Product ID: HY-161015. | |
| JAK2-IN-7 | JAK2-IN-7 is a selective JAK2 inhibitor with IC50s of 3, 11.7, and 41 nM for JAK2, SET-2, and Ba/F3V617F cells, respectively. JAK2-IN-7 possesses >14-fold selectivity over JAK1, JAK3, FLT3. JAK2-IN-7 stimulates cell cycle arrest in the G0/G1 phase and induces tumor cellapoptosis. Antitumor activities[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2593402-36-7. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-131906. | |
| JAK2 JH2 binder-1 | JAK2 JH2 binder-1 (compound 11) is a potent and selective JAK2 JH2 binder, with a Kd of 37.1 nM. JAK2 JH2 binder-1 has the potential for various myeloproliferative neoplasms research[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2923309-41-3. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-146186. | |
| JAK2 JH2 Tracer | JAK2 JH2 Tracer (Tracer 5) is a fluorescent probe for JAK2 JH2 domain, with a Kd value of 0.2 μM[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2101955-00-2. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 50 mg. Product ID: HY-102055. | |
| JAK2/TYK2-IN-1 | JAK2/TYK2-IN-2 is a potent and selective TYK2 inhibitor with IC50 values of 9 and 157 nM for TYK2 and JAK2, respectively. JAK2/TYK2-IN-2 has anti-inflammatory activity[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2613434-12-9. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-143884. | |
| JAK-IN-20 | JAK-IN-20 is a potent, pan and orally active JAK inhibitor with an IC50s of 7 nM, 5 nM, 14 nM for JAK1, JAK2, JAK3, respectively. JAK-IN-20 shows excellent pharmacokinetics and displays anti-inflammatory efficacy in vivo[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1654776-91-6. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-143444. | |
| JAK-IN-5 hydrochloride | JAK-IN-5 hydrochloride is an inhibitor of JAK extracted from patent US20170121327A1, compound example 283[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2751323-21-2. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-111471A. | |
| Janelia Fluor® 549 TFA | Janelia Fluor® 549 TFA (JF549 TFA) is a fluorescent dye with the absorption maximum (λab (max)) of 549 nm and emission maximum (λem (max)) of 571 nm[1]. Janelia Fluor® products are licensed under U.S. Pat. Nos. 9,933,417, 10,018,624 and 10,161,932 and other patents from Howard Hughes Medical Institute. Uses: Scientific research. Category: Signaling pathways. Alternative Names: JF549 TFA. CAS No. 2245946-45-4. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg. Product ID: HY-131022. | |
| Janelia Fluor® 646, SE | Janelia Fluor 646, SE (JF646, SE) is a red fluorescent dye can be used in cellular imaging[1]. Janelia Fluor products are licensed under U.S. Pat. Nos. 9,933,417, 10,018,624 and 10,161,932 and other patents from Howard Hughes Medical Institute. Uses: Scientific research. Category: Signaling pathways. Alternative Names: JF646, SE; JF646, NHS. CAS No. 1811539-59-9. Pack Sizes: 1 mg; 2 mg; 5 mg; 10 mg. Product ID: HY-130735. | |
| Janelia Fluor® 646, Tetrazine | Janelia Fluor 646, Tetrazine (JF646, Tetrazine) a red fluorescent dye that contains a tetrazine group. JF646, Tetrazine can be used in cellular imaging[1]. Janelia Fluor products are licensed under U.S. Pat. Nos. 9,933,417, 10,018,624 and 10,161,932 and other patents from Howard Hughes Medical Institute. Janelia Fluor? 646, Tetrazine is a click chemistry reagent, it contains a Tetrazine group that can undergo an inverse electron demand Diels-Alder reaction (iEDDA) with molecules containing TCO groups. Uses: Scientific research. Category: Signaling pathways. Alternative Names: JF646, Tetrazine. CAS No. 2042192-00-5. Pack Sizes: 200 μg; 500 μg; 1 mg. Product ID: HY-138659. | |
| JANEX-1 | JANEX-1 (WHI-P131) is a potent and specific JAK3 inhibitor (estimated Ki=2.3 μM). JANEX-1 (WHI-P131) shows potent JAK3-inhibitory activity (IC50 of 78 μM), does not inhibit JAK1 and JAK2. Uses: Scientific research. Category: Signaling pathways. Alternative Names: WHI-P131; Jak3 inhibitor I. CAS No. 202475-60-3. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 250 mg; 500 mg. Product ID: HY-15508. | |
| Jarin-1 | Jarin-1 is a jasmonic acid-amido synthetase (JAR1) inhibitor with an IC50 of 3.8 μM. Jarin-1 specific inhibits bioactive JA (jasmonoyl-isoleucine, JA-Ile) biosynthesis in Arabidopsis and other plants[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1212704-51-2. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-115521. | |
| (±)-Jasmonic acid | (±)-Jasmonic acid is an endogenous growth regulator closely related to plant resistance to abiotic stresses, used to activate defense responses to wounding, herbivory, and pathogen attacks. (±)-Jasmonic acid does not play an independent regulatory role, but works in a complex signaling network with other plant hormone signaling pathways. In addition, (±)-Jasmonic acid can also reduce chlorophyll levels in green and etiolated barley leaf segments and inhibit the elongation of rice seedlings[1][2][3][4]. Uses: Scientific research. Category: Signaling pathways. CAS No. 77026-92-7. Pack Sizes: 25 mg (2.38 M * 50 μL in Ethanol); 50 mg (2.38 M * 100 μL in Ethanol); 100 mg (2.38 M * 200 μL in Ethanol); 250 mg (2.38 M * 500 μL in Ethanol). Product ID: HY-122464. | |
| Jasmonic acid | Jasmonic acid ((-)-Jasmonic acid) is a plant growth regulator and a derivative of Linolenic acid (HY-N0728). Jasmonic acid enhances plant resistance and is widely used as a stress protectant. Jasmonic acid is an endogenous plant hormone and a plant growth inhibitor[1][2][3]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: (-)-Jasmonic acid. CAS No. 6894-38-8. Pack Sizes: 1 mg; 5 mg. Product ID: HY-122464A. | |
| Jaspamycin | Jaspamycin (7-CN-7-C-Ino) is a potent activator of PKA, binding to the R site (PKAR), with an EC50 of 6.5 nM and Kd of 8 nM in Trypanosoma brucei. Jaspamycin (7-CN-7-C-Ino) does not bind with purified human PKARIα. Anti-parasite activity[1]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: 7-CN-7-C-Ino. CAS No. 22242-96-2. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-111759. | |
| Jasplakinolide | Jasplakinolide is a potent actin polymerization inducer and stabilizes pre-existing actin filaments. Jasplakinolide binds to F-actin competitively with phalloidin with a Kd of 15 nM. Jasplakinolide, a naturally occurring cyclic peptide from the marine sponge, has both fungicidal and anti-cancer activity[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 102396-24-7. Pack Sizes: 50 μg; 100 μg. Product ID: HY-P0027. | |
| JB-1 | JB-1, an IGF-I analog, is a selective IGF-I receptor inhibitor that does not interact with IGF-II. JB-1 competes with IGF-I for binding to IGF-1R and blocks receptor autophosphorylation. JB-1 increases the level of sVEGFR-1. JB-1 normalizes retinal abnormalities, including reducing retinal neovascularization. JB-1 is applicable to studies related to oxygen-induced retinopathy[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 147819-32-7. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-P3226. | |
| JB170 | JB170 is a potent and highly specific PROTAC-mediated AURORA-A (Aurora Kinase) degrader (DC50=28 nM) by linking Alisertib, to the Cereblon-binding molecule Thalidomide. JB170 preferentially binds AURORA-A (EC50=193 nM) over AURORA-B (EC50=1.4 μM). JB170-mediated S-phase arrest is caused specifically by AURORA-A depletion. JB170 has excellent ability to inhibit non-catalytic function of AURORA-A kinase[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2705844-82-0. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-141512. | |
| JB-95 | JB-95, a β-hairpin macrocyclic peptide, exhibits potent antimicrobial activity against Escherichia coli. JB-95 can selectively disrupt the outer membrane but not the inner membrane of E. coli[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1873323-60-4. Pack Sizes: 5 mg; 10 mg. Product ID: HY-P5753. | |
| JBI-589 | JBI-589 is a non-covalent PAD4 isoform-selective inhibitor with oral bioavailability. JBI-589 reduces CXCR2 expression and blocks neutrophil chemotaxis. JBI-589 reduces primary tumor and metastases, and enhances the anti-tumor effect of checkpoint inhibitors. JBI-589 can be used in cancer research[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2308504-22-3. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg. Product ID: HY-153450. | |
| JBSNF-000028 free base | JBSNF-00002 free base is an orally active small molecule inhibitor of the tricyclic nicotinamide N-methyltransferase (NNMT) with IC50 values for human, mouse and monkey sources of NNMT of 33, 210 and 190 nM respectively. JBSNF-00002 free base can reduce endogenous MNA levels in U2OS osteosarcoma cells, with its EC50 being 2.5 μM. JBSNF-00002 free base exhibits significant anti-obesity and anti-diabetic activities in the diet-induced obesity (DIO) model. JBSNF-00002 free base can be used for the study of metabolic diseases such as obesity, type 2 diabetes and non-alcoholic fatty liver disease[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 3026599-90-3. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg. Product ID: HY-151500. | |
| JBSNF-000088 | JBSNF-000088 (6-Methoxynicotinamide), a analog of nicotinamide (NA), is a potent and orally active Nicotinamide N-methyltransferase (NNMT) inhibitor with IC50s of 1.8 μM, 2.8 μM, and 5.0?μM for human NNMT, monkey NNMT and mouse NNMT, respectively. JBSNF-000088 inhibits NNMT activity, reduces MNA levels and drives insulin sensitization, glucose modulation and body weight reduction in animal models of metabolic disease[1]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: 6-Methoxynicotinamide. CAS No. 7150-23-4. Pack Sizes: 10 mM * 1 mL in DMSO; 25 mg; 50 mg; 100 mg; 200 mg; 500 mg. Product ID: HY-112584. | |
| JC-1 | JC-1 (CBIC2) is an ideal fluorescent probe widely used to detect mitochondrial membrane potential. JC-1 accumulates in mitochondria in a potential dependent manner and can be used to detect the membrane potential of cells, tissues or purified mitochondria. In normal mitochondria, JC-1 aggregates in the mitochondrial matrix to form a polymer, which emits strong red fluorescence (Ex=585 nm, Em=590 nm); When the mitochondrial membrane potential is low, JC-1 cannot aggregate in the matrix of mitochondria and produce green fluorescence (ex=510 nm, em= 527 nm)[1]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: CBIC2. CAS No. 3520-43-2. Pack Sizes: 2 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-15534. | |
| JCN037 | JCN037 (JGK037) is non-covalent and BBB-penetrant EGFR tyrosine kinase inhibitor, with IC50 values of 2.49 nM, 3.95 nM, 4.48 nM for EGFR, p-wtEGFR and pEGFRv?, respectively[1]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: JGK037. CAS No. 2305154-31-6. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-136430. | |
| JD-5037 | JD-5037 is a potent CB1R antagonist with an IC50 of 1.5 nM. Uses: Scientific research. Category: Signaling pathways. CAS No. 1392116-14-1. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-18697. | |
| JDTic dihydrochloride | JDTic (dihydrochloride) is a potent antagonist of kappa-opioid receptors (KOR), blocking the κ-agonist U50, 488-induced antinociception. Uses: Scientific research. Category: Signaling pathways. CAS No. 785835-79-2. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-10487. | |
| Jedi2 | Jedi2 is a Piezo1 activator, but not a specific Piezo2 activator. Jedi2 binds to the mouse Piezo1 proteins with a Kd of 2770??μM[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 651005-90-2. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-131018. | |
| JET-209 | JET-209 is a potent CBP/p300 PROTAC degrader, with DC50 values of 0.05 nM and 0.2 nM for CBP and p300. JET-209 demonstrates remarkable anti-tumor activity against various acute leukemia cell lines and effectively inhibits tumor growth in xenograft tumor models. JET-209 can be used for the study of acute leukemia[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 3033714-58-5. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg. Product ID: HY-154984. | |
| JG-2016 | JG-2016 is a potent inhibitor of histone acetyltransferase 1 (HAT1) with an IC50 of 14.8 μM. JG-2016 can inhibit the growth of multiple tumor cells and has anti-tumor activity[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2887480-87-5. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-154944. | |
| JG-231 | JG-231 is an allosteric inhibitor of heat shock protein 70 (Hsp70). JG - 231 inhibits the binding of Hsp70 and BAG family proteins, including inhibition of Hsp70 and BAG1 with a Ki of 0.11 μM. JG-231 inhibits proliferation of tumor cells and induces apoptosis. JG-231 has antitumor activity[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1627126-59-3. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-124611. | |
| JG26 | JG26 is an ADAM inhibitor with IC50 values of 12 nM, 1.9 nM, and 150 nM for ADAM8, ADAM17, and ADAM10, respectively. JG26 inhibits MMP-12 with an IC50 value of 9.4 nM. JG26 inhibits AngII (HY-13948)-induced EGFR transactivation and ERK activation. JG26 increases the expression of ACE2, inhibits the cleavage of CD23, reduces the infection of SARS-CoV-2. JG26 inhibits colorectal cancer metastasis. JG26 can be used for research on Hodgkin lymphoma and vascular diseases[1][2][3][4][5][6]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1464910-32-4. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-120852. | |
| JG-98 | JG-98, an allosteric heat shock protein 70 (Hsp70) inhibitor, which binds tightly to a conserved site on Hsp70 and disrupts the Hsp70-Bag3 interaction. JG-98 shows anti-cancer activities affecting both cancer cells and tumor-associated macrophages[1][2][3]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1456551-16-8. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-117282. | |
| JH295 | JH295 is a potent, irreversible and selective NIMA-related kinase 2 (Nek2) inhibitor with an IC50 of 770 nM. JH295 inhibits cellular Nek2 via alkylation of Cys22. JH295 is inactive against the mitotic kinases, Cdk1, Aurora B or Plk1, and does not perturb bipolar spindle assembly or the spindle assembly checkpoint[1]. JH295 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups. Uses: Scientific research. Category: Signaling pathways. CAS No. 1311143-71-1. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-116423. | |
| JH-II-127 | JH-II-127 is an orally active, highly potent, selective and brain-permeable LRRK2 inhibitor, with IC50s of 6, 2 and 48 nM for wild-type LRRK2 and LRRK2-G2019S and mutant LRRK2-A2016T. JH-II-127 inhibits Ser935 phosphorylation in all tissues of mice, including the brain. JH-II-127 can be used in the study of parkinson's syndrome[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1700693-08-8. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-16936. | |
| JH-LPH-107 | JH-LPH-107 is a LpxH inhibitor. JH-LPH-107 exhibits a low rate of spontaneous resistance and a high safety window in vitro.[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 3053068-92-8. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-168649. | |
| JH-LPH-28 | JH-LPH-28, a sulfonyl piperazine analog, is a potent UDP-2,3-diacylglucosamine pyrophosphate hydrolase LpxH inhibitor. JH-LPH-28 displays outstanding antibiotic activity with a MIC value of 0.83 μg/mL[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2414592-36-0. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-130837. | |
| JH-LPH-33 | JH-LPH-33, a sulfonyl piperazine analog, is a potent UDP-2,3-diacylglucosamine pyrophosphate hydrolase LpxH inhibitor. JH-LPH-33 displays outstanding antibiotic activity with a MIC value of 0.66 μg/mL[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2414590-04-6. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-130838. | |
| JH-RE-06 | JH-RE-06, a potent REV1-REV7 interface inhibitor (IC50=0.78 μM; Kd=0.42 μM), targets REV1 that interacts with the REV7 subunit of POLζ. JH-RE-06 disrupts mutagenic translesion synthesis (TLS) by preventing recruitment of mutagenic POLζ. JH-RE-06 improves chemotherapy[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1361227-90-8. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-126214. | |
| JHU-083 | JHU-083, a proagent of 6-diazo-5-oxo-L-norleucine (DON; HY-108357), is an orally active and selective glutaminase antagonist. JHU-083 blocks glutaminase activity in brain CD11b+ cells and experimental cerebral malaria (ECM) resulting in a net decrease of glutamate levels in the animals[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1998725-11-3. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-122218. | |
| JHU395 | JHU395 is an orally-bioavailable and a plasma stable lipophilic glutamine antagonists (GA) proagent. JHU395 delivers 6-diazo-5-oxo-L-norleucine (DON) to malignant peripheral nerve sheath tumor (MPNST) in vitro and in vivo, and has antitumor activity in MPNST[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2079938-92-2. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 1 g. Product ID: HY-128775. | |
| JH-X-119-01 | JH-X-119-01 is a potent and selective interleukin-1 receptor-associated kinases 1 (IRAK1) inhibitor. JH-X-119-01 ameliorates LPS-induced sepsis in mice[1]. JH-X-119-01 inhibits IRAK1 biochemically with an apparent IC50 of 9 nM while exhibiting no inhibition of IRAK4 at concentrations up to 10 μM[2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2227368-54-7. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-103017A. | |
| JH-X-119-01 hydrochloride | JH-X-119-01 hydrochloride is a potent and selective interleukin-1 receptor-associated kinases 1 (IRAK1) inhibitor. JH-X-119-01 hydrochloride ameliorates LPS-induced sepsis in mice[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2591344-30-6. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 50 mg. Product ID: HY-103017. | |
| JH-XI-10-02 | JH-XI-10-02 is a PROTAC connected by ligands for Cereblon and CDK. JH-XI-10-02 is a highly potent and selective PROTAC CDK8 degrader, with an IC50 of 159 nM. JH-XI-10-02 causes proteasomal degradation, does not affect CDK8 mRNA levels. JH-XI-10-02 shows no effect on CDK19[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2209085-22-1. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg. Product ID: HY-111518. | |
| JH-XII-03-02 | JH-XII-03-02 is a potent and selective LRRK2 PROTAC degrader. JH-XII-03-02 can be used for parkinson's Disease (PD) research[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2415900-86-4. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg. Product ID: HY-155150. | |
| JH-XVI-178 | JH-XVI-178 is a highly efficient and selective CDK8/19 inhibitor, with IC50 values of 1 and 2 nM for CDK8 and CDK19, respectively. JH-XVI-178 has a low clearance rate and moderate oral pharmacokinetic properties[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2648453-53-4. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-139875. | |
| JI051 | JI051 is a stabilizer for the Hes1-PHB2 interaction. JI051 interacts with a cancer-associated protein chaperone prohibitin 2 (PHB2), induces cell-cycle arrest by inhibiting the Notch downstream effector gene Hes1. Anti-cancer activity[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2234281-75-3. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-117113. | |
| JI-101 | JI-101 is an orally available multi-kinase inhibitor of VEGFR2, PDGFRβ and EphB4 with potent anti-cancer activity. Uses: Scientific research. Category: Signaling pathways. CAS No. 900573-88-8. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-16265. | |
| JIB-04 | JIB-04 is a pan-selective Jumonji histone demethylase inihibitor with IC50s of 230, 340, 855, 445, 435, 1100, and 290 nM for JARID1A, JMJD2E, JMJD3, JMJD2A, JMJD2B, JMJD2C, and JMJD2D, respectively. Uses: Scientific research. Category: Signaling pathways. CAS No. 199596-05-9. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-13953. | |
| JJH260 | JJH260 is AIG1inhibitor, and inhibit the fluorophosphonate reactivity and fatty acid esters of hydroxy fatty acid (FAHFA) hydrolysis activity of AIG1in HEK293T cells, with IC50 values of 0.50 μM and 0.57 μM, respectively[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1831135-30-8. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-116895. | |
| JKC363 | JKC363, a selective melanocortin MC4 receptor antagonist, has a 90-fold higher affinity at the MC4 receptor (IC50=0.5 nM) than at the MC3 receptor (44.9 nM). JKC-363 blocks the stimulatory effect of α-MSH on TRH release. Anti-hyperalgesic effect[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 436083-30-6. Pack Sizes: 5 mg; 10 mg. Product ID: HY-P1213. | |
| JKE-1674 | JKE-1674 is an orally active glutathione peroxidase 4 (GPX4) inhibitor and an active metabolite of GPX4 inhibitor ML-210. JKE-1674, an analog of ML-210 in which the nitroisoxazole ring is replaced with an α-nitroketoxime. JKE-1674 can convert into a nitrile oxide JKE-1777. JKE-1674 kills LOX-IMVI cells in a manner that is equipotent to ML-210 and is completely rescued by ferroptosis inhibitors[1][2][3]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2421119-60-8. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-138153. | |
| JMJD1C-IN-1 | JMJD1C-IN-1 is an orally active and selective inhibitor of JMJD1C (IC50 = 0.59 μM, Kd = 1.96 μM). JMJD1C-IN-1 inhibits the binding of JMJD1C to H3K9me2 peptide substrate in the HTRF assay (IC50 = 1.47 μM). JMJD1C-IN-1 disrupts intratumoral regulatory T (Treg) cell fitness by dual mechanisms: promoting H3K9me2 accumulation to downregulate PD1 expression and reducing STAT3 demethylation to enhance STAT3 activation. JMJD1C-IN-1 demonstrates dose-dependent antitumor efficacy in multiple mouse tumor models (MCA205 fibrosarcoma, B16-F10 melanoma, LLC lung cancer, Hepa1-6 hepatocellular carcinoma, CT26 colorectal cancer). JMJD1C-IN-1 can be used for the study of tumor immunotherapy by selectively targeting intratumoral Treg cells[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 861224-48-8. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-162275. | |
| JMJD6-IN-1 | JMJD6-IN-1 is a JMJD6 inhibitor, with an inhibition rate of 82% at 10 μM. JMJD6-IN-1 inhibits MCF-7 and HCC4006 cell proliferation with IC50 values of 19.2 μM and 25.2 μM. JMJD6-IN-1 inhibits JMJD6 demethylase activity. JMJD6-IN-1 can be used for the research of lung adenocarcinoma, prostate cancer, breast cancer, pancreatic cancer, colon cancer, oral squamous cell carcinoma, and glioblastoma[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 899548-78-8. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg. Product ID: HY-139434. | |
| JMS-053 | JMS-053 is an efficient and reversible PTP4A3 inhibitor, with an IC50 value of 18 nM.JMS-053 demonstrates broad PTP4A inhibitory activity with IC50s of 50 nM and 53 nM for PTP4A1 and PTP4A2, respectively. JMS-053 exhibits IC50 values of 92.6 nM and 207.6 nM for CDC25B and DUSP3, respectively. JMS-053 can effectively inhibit the activity of PTP4A3, inhibit tumor cell proliferation and migration through multiple mechanisms such as interfering with RhoA and STAT3/p38 signaling pathway. JMS-053 can be used for the study of cancers such as ovarian cancer, breast cancer and colon cancer[1][2][3][4][5]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1954650-11-3. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-135457. | |
| JMS-17-2 | JMS-17-2 is a potent and selective CX3CR1 antagonist with an IC50 of 0.32 nM. JMS-17-2 impairs metastatic seeding and colonization of breast cancer cells[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1380392-05-1. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-123918. | |
| JMV 2959 | JMV 2959 is a growth hormone secretagogue receptor type 1a (GHS-R1a) antagonist with an IC50 of 32 nM. Uses: Scientific research. Category: Signaling pathways. CAS No. 925238-89-7. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-U00433. | |
| JMV 2959 hydrochloride | JMV 2959 hydrochloride is a growth hormone secretagogue receptor type 1a (GHS-R1a) antagonist with an IC50 of 32±3 nM in LLC-PK1 cells. Uses: Scientific research. Category: Signaling pathways. CAS No. 2448414-54-6. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg. Product ID: HY-U00433A. | |
| JND3229 | JND3229 is a reversible EGFRC797S inhibitor with IC50 values of 5.8, 6.8 and 30.5 nM for EGFRL858R/T790M/C797S, EGFRWT and EGFRL858R/T790M, respectively. JND3229 has good anti-proliferative activity and can effectively inhibit tumour growth in vivo. JND3229 can be used in cancer research, especially in non-small cell carcinoma[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2260886-64-2. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-119944. | |
| JNJ0966 | JNJ0966 is a highly selective MMP-9 zymogen inhibitor with an IC50 of 440 nM. Uses: Scientific research. Category: Signaling pathways. CAS No. 315705-75-0. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-103482. | |
| JNJ-1013 | JNJ-1013 is a potent and selective IRAK1 PROTAC degrader with an IC50s of 72, 443, 1071 nM for IRAK1, IRAK4, VHL FP respectively. JNJ-1013 induces apoptosis and increases the expression of cleavaged PARP. JNJ-1013 decreases the expression IRAK1, p-IKBα, pSTAT3(Tyr705) (Pink: ligand for target protein (HY-138834); black: linker (HY-Y1760); Blue: E3 ligase ligand (HY-112078))[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2597343-08-1. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-153188. | |
| JNJ-10229570 | JNJ-10229570 is an antagonist of melanocortin receptor 1 (MC1R) and melanocortin receptor 5 (MC5R), which inhibits sebaceous gland differentiation and the production of sebum-specific lipids. JNJ-10229570 inhibits the binding of 125I-NDP-α-MSH to cells expressing human MC1R and MC5R, with IC50 values of 270 nM and 200 nM, respectively. Uses: Scientific research. Category: Signaling pathways. CAS No. 524923-88-4. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-107139. | |
| JNJ-1289 | JNJ-1289 is a potent, selective, competitive and allosteric human spermine oxidase (hSMOX) inhibitor (IC50: 50 nM). JNJ-1289 can be used in the research of polyamine catabolism, inflammation and cancers[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 792898-18-1. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-151115. | |
| JNJ-16241199 | JNJ-16241199 (R306465) is an orally active, selectivehydroxamate-based histone deacetylase (HDAC) inhibitor, with theIC50of 3.3 nM and 23 nM for HDAC1and HDAC8, respectively.JNJ-16241199induces histone 3 acetylation and strongly increasesthe expression of p21waf1, cip1 in A2780 ovarian carcinoma cells.JNJ-16241199 inducescell apoptosisand shows anticancer activityin a broad spectrum of human malignancies. JNJ-16241199 can be used for cancer study[1]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: R306465. CAS No. 604769-01-9. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg. Product ID: HY-10226. | |
| JNJ16259685 | JNJ16259685 is a selective antagonist of mGlu1 receptor, and inhibits the synaptic activation of mGlu1 in a concentration-dependent manner with IC50 of 19 nM. Uses: Scientific research. Category: Signaling pathways. CAS No. 409345-29-5. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-100407. | |
Would you like to list your products on USA Chemical Suppliers?
Our database is helping our users find suppliers everyday.